Migraine disease: evolution and progression

Buzzi, Maria Gabriella; Cologno, Daniela; Formisano, Rita

doi:10.1007/s10194-005-0215-9

Cited by 9 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also favours a central dysfunction in these primary headaches. First, in migraine, the observed cognitive deficiencies have been extended to attention and memory, which accords with the proposal that migraine is a brain disease (26, 27). Second, the central problem has also been described in the pathophysiology of CTTH (28, 29).…”

Section: Discussionsupporting

confidence: 75%

Passive Paradigm Single-Tone Elicited ERPs in Tension-Type Headaches and Migraine

Chen

Shen

Liu³

et al. 2007

Cephalalgia

View full text Add to dashboard Cite

The active 'oddball' event-related potential (ERP) P3 is elongated or reduced in migraine and tension-type headaches, indicating a deficit of active attention in these primary headaches. It is then reasonable to study the passive attention function in these headaches through the technology of passive paradigm single-tone elicited ERPs. We invited 32 patients suffering from chronic tension-type headache (CTTH), 17 from frequent episodic tension-type headache (FETH) and 32 from interictal migraine without aura, as well as 28 healthy subjects to undergo passive paradigm single-tone ERPs. There were no statistically significant differences when the mean latencies and amplitudes of N1, P2, N2 or the mean latencies of P3 of the four groups were considered. In contrast, the P3 amplitudes were significantly reduced in the patient groups when compared with healthy controls. However, no further significant difference was found between patient groups when considering P3 amplitude. Our study demonstrated a deficit of passive attention in CTTH, FETH and migraine, but could not separate these headache types in this regard. The reduced P3 in patients might be due to the head pain experienced.

show abstract

Section: Discussionsupporting

confidence: 75%

Passive Paradigm Single-Tone Elicited ERPs in Tension-Type Headaches and Migraine

Chen

Shen

Liu³

et al. 2007

Cephalalgia

View full text Add to dashboard Cite

show abstract

“…Open channels allow cation (sodium and calcium) influx and action potential discharge ( 151 , 152 ). (B) TRPV1-expression is stimulated by inflammatory eicosanoids, bradykinin, histamine, and others ( 4 ). Allergic sensitization with aerosolized allergen induces the expression of TRPV1 channels in both Aβ low-threshold mechanosensory fibers and Aδ cough fibers.…”

Section: The Role Of Mast Cells In Painmentioning

confidence: 99%

Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology

et al. 2016

View full text Add to dashboard Cite

Migraine is a common, little understood, and debilitating disease. It is much more prominent in women than in men (~2/3 are women) but the reasons for female preponderance are not clear. Migraineurs frequently experience severe comorbidities, such as allergies, depression, irritable bowel syndrome, and others; many of the comorbidities are more common in females. Current treatments for migraine are not gender specific, and rarely are migraine and its comorbidities considered and treated by the same specialist. Thus, migraine treatments represent a huge unmet medical need, which will only be addressed with greater understanding of its underlying pathophysiology. We discuss the current knowledge about sex differences in migraine and its comorbidities, and focus on the potential role of mast cells (MCs) in both. Sex-based differences in pain recognition and drug responses, fluid balance, and the blood–brain barrier are recognized but their impact on migraine is not well studied. Furthermore, MCs are well recognized for their prominent role in allergies but much less is known about their contributions to pain pathways in general and migraine specifically. MC-neuron bidirectional communication uniquely positions these cells as potential initiators and/or perpetuators of pain. MCs can secrete nociceptor sensitizing and activating agents, such as serotonin, prostaglandins, histamine, and proteolytic enzymes that can also activate the pain-mediating transient receptor potential vanilloid channels. MCs express receptors for both estrogen and progesterone that induce degranulation upon binding. Furthermore, environmental estrogens, such as Bisphenol A, activate MCs in preclinical models but their impact on pain pathways or migraine is understudied. We hope that this discussion will encourage scientists and physicians alike to bridge the knowledge gaps linking sex, MCs, and migraine to develop better, more comprehensive treatments for migraine patients.

show abstract

“…Migraine is a complex disorder with several phenotypes and different clinical features during the patient's lifetime [Buzzi et al, 2005a]. According to the latest international guidelines [Headache Classification Subcommittee of the International Headache Society, 2004], migraine phenotypes can be coded in 19 subtypes characterized by unique features.…”

Section: Introductionmentioning

confidence: 99%

Triptan efficacy in migraine attacks: from appropriate diagnosis to metabolic profiles and pharmacogenomics

Buzzi

2007

Drug Development Research

View full text Add to dashboard Cite

A major, revolutionary advance in acute migraine therapy was the development of sumatriptan, a selective 5-HT1B/1D receptor agonist. After sumatriptan, the so-called second generationtriptans have become available and at present 7 triptans are on the market. Activation of the trigeminal nerve is a key component of the cascade that leads to, and perpetuates, a migraine attack. Sumatriptan and the other triptans currently on the market (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) are potent agonists of the 5-HT1B and 5-HT1D receptors, and some are potent 5-HT1F agonists. The use of a variety of endpoints for a certain drug, measuring treatment success in terms of both efficacy and tolerability, should aid in the selection of agents that can offer patients the highest likelihood of consistent treatment success. Further possibilities are offered by studying metabolic profiles of molecules in order to tailor the best treatment option for each patient, and obtain the best efficacy profiles and the lower rate of drug-adverse events. Drug Dev Res 68: 335-340, 2007.

show abstract

Migraine disease: evolution and progression

Cited by 9 publications

References 20 publications

Passive Paradigm Single-Tone Elicited ERPs in Tension-Type Headaches and Migraine

Passive Paradigm Single-Tone Elicited ERPs in Tension-Type Headaches and Migraine

Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology

Triptan efficacy in migraine attacks: from appropriate diagnosis to metabolic profiles and pharmacogenomics

Contact Info

Product

Resources

About